Welcome
Disease Activated Therapeutics: Next generation medicines for the management of diseases of the central nervous system.
NeurOp is a preclinical stage pharmaceutical company developing proprietary disease activated small molecules for the treatment of CNS disease. NeurOp’s most advanced compounds demonstrate in vivo efficacy in animal models of neuropathic pain and ischemia with no apparent toxicity at therapeutic doses. NeurOp has offices and laboratory facilities in EmTech Bio, a life sciences incubator located on the campus of Emory University in Atlanta, Georgia.
Years of basic research performed by the NeurOp founders, Drs. Raymond Dingledine and Stephen Traynelis of the Emory University Department of Pharmacology, and Dr. James McNamara, Chairman of the Neurobiology Department at the Duke University Medical Center, underpin NeurOp’s technology. Discoveries made by NeurOp’s founders through intensive investigation of a critical signaling pathway in the CNS, inspired concepts and designs for improved, safer drugs to treat neuropathic pain, ischemia and neurodegenerative disease.
In 2000, the NeurOp founders initiated a collaboration with Dr. Dennis Liotta, a professor in the Emory Department of Chemistry to translate these promising concepts into medicines. Dr. Liotta is a renowned medicinal chemist and has helped discover and develop several pharmaceuticals currently in use or undergoing clinical evaluation. About 75% of all HIV patients worldwide are treated with antiviral compounds discovered or developed in Dr. Liotta’s lab. The founders’ fruitful collaboration with Dr. Liotta produced a series of compounds that when tested in animals, validated NeurOp’s strategies for developing safer therapeutics. While the founders and Dr. Liotta continue their academic collaboration, NeurOp staff scientists are refining promising leads to create safe and effective therapeutics.
Home - Our Team - Technology - Markets and Indications - Funding Strategy - Press Releases - Contact Us